1 | visitas reunion academica scom | | | | | | | 4 | 1.07% |
2 | 22893 visitas reunion academica | | | | | | | 2 | 0.53% |
3 | visitas reunion academica scomabril | | | | | | | 2 | 0.53% |
4 | reunion academica scomabril 2024 | | | | | | | 2 | 0.53% |
5 | academica scomabril 2024 20240404 | | | | | | | 2 | 0.53% |
6 | scomabril 2024 20240404 post | | | | | | | 2 | 0.53% |
7 | topotecÁn ciclofosfamida estudio reecur | | | | | | | 1 | 0.27% |
8 | abre una puerta a | | | | | | | 1 | 0.27% |
9 | estudio abre una puerta | | | | | | | 1 | 0.27% |
10 | visitas estudio abre una | | | | | | | 1 | 0.27% |
11 | 22789 visitas estudio abre | | | | | | | 1 | 0.27% |
12 | ciclofosfamida estudio reecur post | | | | | | | 1 | 0.27% |
13 | sg vs topotecÁn ciclofosfamida | | | | | | | 1 | 0.27% |
14 | vs topotecÁn ciclofosfamida estudio | | | | | | | 1 | 0.27% |
15 | puerta a una vacuna | | | | | | | 1 | 0.27% |
16 | la sg vs topotecÁn | | | | | | | 1 | 0.27% |
17 | y la sg vs | | | | | | | 1 | 0.27% |
18 | sle y la sg | | | | | | | 1 | 0.27% |
19 | la sle y la | | | | | | | 1 | 0.27% |
20 | una puerta a una | | | | | | | 1 | 0.27% |
21 | a una vacuna universal | | | | | | | 1 | 0.27% |
22 | de ewing rr ifosfamida | | | | | | | 1 | 0.27% |
23 | tus pulmones tÚ puedes | | | | | | | 1 | 0.27% |
24 | cÁncer de pulmÓn inscrÍbase | | | | | | | 1 | 0.27% |
25 | el cÁncer de pulmÓn | | | | | | | 1 | 0.27% |
26 | tiempo el cÁncer de | | | | | | | 1 | 0.27% |
27 | a tiempo el cÁncer | | | | | | | 1 | 0.27% |
28 | detectar a tiempo el | | | | | | | 1 | 0.27% |
29 | y detectar a tiempo | | | | | | | 1 | 0.27% |
30 | prevenir y detectar a | | | | | | | 1 | 0.27% |
31 | a tus pulmones tÚ | | | | | | | 1 | 0.27% |
32 | una vacuna universal contra | | | | | | | 1 | 0.27% |
33 | respiro a tus pulmones | | | | | | | 1 | 0.27% |
34 | un respiro a tus | | | | | | | 1 | 0.27% |
35 | da un respiro a | | | | | | | 1 | 0.27% |
36 | visitas da un respiro | | | | | | | 1 | 0.27% |
37 | 22783 visitas da un | | | | | | | 1 | 0.27% |
38 | post 22783 visitas da | | | | | | | 1 | 0.27% |
39 | cÁncer post 22783 visitas | | | | | | | 1 | 0.27% |
40 | vacuna universal contra el | | | | | | | 1 | 0.27% |